Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-19-122384
Filing Date
2019-04-26
Accepted
2019-04-26 16:16:04
Documents
10
Period of Report
2019-06-11
Effectiveness Date
2019-04-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A d716135ddef14a.htm DEF 14A 372084
2 GRAPHIC g716135g21p68.jpg GRAPHIC 21466
3 GRAPHIC g716135g44n79.jpg GRAPHIC 27301
4 GRAPHIC g716135g46o31.jpg GRAPHIC 14905
5 GRAPHIC g716135g47q94.jpg GRAPHIC 25145
6 GRAPHIC g716135g50m35.jpg GRAPHIC 14780
7 GRAPHIC g716135g80r17.jpg GRAPHIC 17822
8 GRAPHIC g716135g85x27.jpg GRAPHIC 24858
9 GRAPHIC g716135g94m68.jpg GRAPHIC 22138
10 GRAPHIC g716135g94s32.jpg GRAPHIC 28617
  Complete submission text file 0001193125-19-122384.txt   645180
Mailing Address 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080
Business Address 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080 (650) 416-7700
Principia Biopharma Inc. (Filer) CIK: 0001510487 (see all company filings)

IRS No.: 263487603 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38653 | Film No.: 19771958
SIC: 2834 Pharmaceutical Preparations